In January 1988, the expert panel of the National Cholesterol Education Program on detection, evaluation, and treatment of high blood cholesterol in adults listed 10 atherosclerotic risk factors predictive of coronary arterial atherosclerotic events. Risk factor No. 4 was "smoking more than 10 cigarettes a day.'1 In populations that have average serum cholesterol levels below 150 mg/dl (e.g., Japan), atherosclerotic events are rare even when cigarette smoking is widespread.2 In a recent article in Circulation, Drs. Stanton Glantz and William Parmley argue that exposure to the extremely low levels of environmental tobacco smoke (ETS) experienced by nonsmokers is a risk factor for heart disease. These authors state that "these results suggest that heart disease is an important consequence of exposure to ETS."
Environmental Tobacco Smoke and Cardiovascular Disease
In January 1988, the expert panel of the National Cholesterol Education Program on detection, evaluation, and treatment of high blood cholesterol in adults listed 10 atherosclerotic risk factors predictive of coronary arterial atherosclerotic events. Risk factor No. 4 was "smoking more than 10 cigarettes a day. ' 1 In populations that have average serum cholesterol levels below 150 mg/dl (e.g., Japan), atherosclerotic events are rare even when cigarette smoking is widespread.2 In a recent article in Circulation, Drs. Stanton Glantz and William Parmley argue that exposure to the extremely low levels of environmental tobacco smoke (ETS) experienced by nonsmokers is a risk factor for heart disease. These authors state that "these results suggest that heart disease is an important consequence of exposure to ETS."
An examination of the results from the 10 epidemiology studies conducted to date does not support the contention that exposure to ETS is a risk factor for heart disease. Of the four studies conducted on males married to women who smoke, three have 95% confidence intervals that go below 1.0 (i.e., no increased risk). The 95% confidence interval of the fourth study, Helsing et al (1988) , goes down to 1.1. Of the eight studies conducted on females married to men who smoke, five have 95% confidence limits that either include or go below 1.0. The 95% confidence limits of the other three studies approach 1.0 with left limit values of 1.1, 1.2, and 1.3. In the one study conducted on both sexes, Hole et al (1989) reported a 95% confidence interval with a left limit of 1.2. Therefore, all of these studies are either statistically insignificant at the 95% level or are marginally significant.
Using the results from the 10 studies, Drs. Glantz and Parmley have estimated a pooled relative risk for coronary heart disease death associated with ETS exposure at 1.3. The eminent statistician Nathan Mantel has stated that relative risks less than 2.0 are subject to bias and confounding and have not been traditionally accepted as indicative of true risk.3 If there is a slight increase in cardiovascular risk between the spouses of smokers and the spouses of nonsmokers, it is readily explainable by studies that have reported that the spouses of smokers consume less betacarotene, less fruits and vegetables, more saturated fat, have a slightly higher mean body mass index, and exercise less than the spouses of nonsmokers.4-6 In the absence of well-controlled epidemiological studies that take these potential confounders into This action makes it virtually impossible for almost all reviewers to establish whether the authors have correctly cited information in these references.
The authors place great emphasis on the role of carbon monoxide (which forms carboxyhemoglobin and therefore reduces oxygen-carrying capacity of blood) in ETS in influencing such effects as angina and lowered exercise performance. Their position is challenged by a recent article6 that concluded that any increases in carboxyhemoglobin (usually less than 2%) in nonsmokers exposed to ETS are very small and of no toxicological relevance for healthy adults.
A study of the increase of a certain blood biochemical (2,3diphosphoglycerate), indicating an attempt of the body to compensate for lower blood oxygen concentration, is cited.7 Although the increase was reported to be statistically significant, it is well within the "normal" (reference) range.8
The reports of ETS causing changes in mitochondrial respiration in rabbit tissues are in vitro studies with very limited application (if any) to whole-body effects, and the implications to human beings are far from clear.
The authors presented no direct evidence that exposure to ETS leads to thrombus formation; they merely speculated that, on the basis of the studies on platelet aggregation that they quoted, such exposure "thus increases the likelihood of thrombus formation and myocardial infarction."
As to the platelet aggregation studies, differences (although reported to be statistically significant) appear to be small, and thus may have little, if any, clinical significance. The authors cited a lack of dose/effect relation with blood nicotine concentrations; this in itself speaks against a causal relation. Furthermore, confounding factors that can increase platelet aggregation, such as traumatic venipuncture, hemolysis, lipemia, and heparin8 do not appear to have been considered.
Platelet sensitivity to antiaggregatory prostaglandins also seems to show only weak effects, and any effects of ETS exposure appear to be quite transient, thus casting doubt on their biological significance.
Ambient air concentrations of ETS or its components studied were not given in most of the articles reviewed. However, concentrations were, by the nature of the experiments, undoubtedly much higher than would be encountered in usual exposures to ETS. The authors' reasoning on possible development of atherosclerosis due to ETS exposure appears to be a great leap in logic. They place great emphasis on increases of appearance of anuclear endothelial cell carcasses in blood of people exposed to ETS but neglect to mention that the clinical relevance of this finding (as well as that of increased platelet aggregation) in regard to initiation of atherosclerosis remains speculative.
The authors' theory on formation of atherosclerotic plaque makes no mention of the studies of Michael S. Brown and Joseph L. Goldstein (University of Texas Southwestern Medical Center, Dallas), who were awarded the Nobel Prize in Physiology or Medicine 2 years ago for their work on the mechanism of such plaque formation. According to these researchers, release of growth factors from platelets, not platelet aggregation or adherence, is the role of platelets in plaque formation. There is no convincing evidence that ETS exposure promotes the release of these growth factors.9
In the discussion of a possible role of polycyclic aromatic hydrocarbons (PAH) in ETS, there are several pitfalls. The authors did not state Remmer's10 conclusions correctly. He actually said that the publications then available on ETS and heart disease "are not convincing because they did not adjust for the different risk factors contributing to ischemic heart disease." Remmer also concluded that the minimal amounts of tobacco smoke particles containing PAH from ETS cannot explain reported adverse health effects. Animal studies cited used chickens and pigeons as models for PAH-induced aortic plaque buildup; it seems appropriate to question the relevance of these birds to human heart disease. Likewise, the relevance of transplantation of human artery plaques to mice must also be questioned. The authors seem to defeat their own argument by stating that "the plaques were taken from adult patients in late states of vascular disease. Thus, we cannot determine from these samples whether the manifestation of transformation is a relatively late event in plaque development or an early but stable event." The Randerath study used a condensate of cigarette "tar," a substance far more concentrated and chemically and physically different from ETS. The chimney sweep study (1983) was available to both the Surgeon General's and National Research Council's panels; neither group discussed it in relation to ETS and heart disease.
From all these considerations, the authors fail to establish that "ETS increases risk of death from heart disease" or that "ETS causes heart disease" through the epidemiological, physiological, and biochemical studies reviewed. Finally, their statement that "this increase in risk translates into about 10 times as many deaths from ETS-induced heart disease as lung cancer" is insufficiently supported by the literature. Rather, it reflects the controversial mathematical model used by Wells.11 Walter J. Decker, PhD Toxicology Consultant Services El Paso, Tex.
Recently, you published an article by Drs. Glantz and Parmley' stating that environmental tobacco smoke (ETS) exposure causes an estimated 53,000 deaths per year. The vast majority of these deaths purportedly arise from cardiovascular disease (CVD) caused by ETS exposure.
Part of this claim comes from the authors' review of epidemiology studies that compared CVD risks with spousal smoking habits. Based on their review, they claim that ETS exposure is responsible for a 30% increase in CVD risk. However, they fail to note that spousal smoking is not the equivalent of ETS exposure.2 They also downplay the facts that the majority of studies fail to report a statistically significant increase in risk and that only a few of the studies attempt to correct for the major recognized CVD risk factors such as cholesterol level, hypertension, blood pressure, and obesity. When the reported relative risk of an exposure is very small, as it is in these studies, it is crucial to be very careful in defining and quantitating exposure, correcting for bias and confounding factors, and ensuring that the results are not due to chance. Glantz and Parmley do none of this.
Glantz and Parmley then go on to cite several studies they claim demonstrate adverse physiological effects resulting from ETS exposure. The relevance of these studies to ETS exposure is questionable at best. In the human studies, there are no measures of ETS concentration and few of exposure duration. Many of the effects reported were minor acute changes with questionable clinical significance. In many of the animal studies, the exposure was via intramuscular injection. Studies that attempted animal inhalation exposures or controlled human exposure studies use exposure levels that appeared to be several orders of magnitude higher than what would normally be observed during real-life ETS exposure.
As in any toxicological exposure evaluation, before one can conclude whether or not an adverse effect can be expected, it is necessary to determine the dose to which one may have been exposed. A relatively new analytical procedure called Ultraviolet-
